王丹津, 郜秋果, 王淑琴, 邓张双, 梁坚家. ACLY抑制剂脱氢弯孢霉菌素的结构改造及抗肿瘤活性研究J. 药学学报, 2025, 60(6): 1799-1806. DOI: 10.16438/j.0513-4870.2024-1286
引用本文: 王丹津, 郜秋果, 王淑琴, 邓张双, 梁坚家. ACLY抑制剂脱氢弯孢霉菌素的结构改造及抗肿瘤活性研究J. 药学学报, 2025, 60(6): 1799-1806. DOI: 10.16438/j.0513-4870.2024-1286
WANG Dan-jin, GAO Qiu-guo, WANG Shu-qin, DENG Zhang-shuang, LIANG Jian-jia. Structural modification and antitumor activity of the ACLY inhibitor dehydrocurvularinJ. Acta Pharmaceutica Sinica, 2025, 60(6): 1799-1806. DOI: 10.16438/j.0513-4870.2024-1286
Citation: WANG Dan-jin, GAO Qiu-guo, WANG Shu-qin, DENG Zhang-shuang, LIANG Jian-jia. Structural modification and antitumor activity of the ACLY inhibitor dehydrocurvularinJ. Acta Pharmaceutica Sinica, 2025, 60(6): 1799-1806. DOI: 10.16438/j.0513-4870.2024-1286

ACLY抑制剂脱氢弯孢霉菌素的结构改造及抗肿瘤活性研究

Structural modification and antitumor activity of the ACLY inhibitor dehydrocurvularin

  • 摘要: 采用全合成和活性药效团拼接的结构修饰策略, 通过傅克酰化、烯烃复分解和脱甲基等反应合成得到11个脱氢弯孢霉菌素(dehydrocurvularin, DCV) 衍生物, 利用核磁共振、高分辨质谱等技术对目标化合物进行了结构表征, 采用CCK-8法测试了ATP-柠檬酸裂解酶高表达的肿瘤细胞活性(乳腺癌MDA-MB-231和肝癌HepG2), 并通过分子模拟讨论了衍生物的构效关系, 其中化合物7e对两种肿瘤细胞的体外抗肿瘤活性均优于DCV, 且可以显著诱导乳腺癌MDA-MB-231细胞发生凋亡; 为该类大环内酯衍生物的结构修饰和构效关系研究奠定基础。

     

    Abstract: A total synthesis of dehydrocurvularin (DCV) demethylated derivatives and structure modification have been completed using a Friedel-Crafts reaction and a highly olefin metathesis reaction. All compounds were identified by NMR, HRMS, etc. Their antitumor activity with high expression of ATP-citrate lyase was evaluated by CCK-8 assay in MDA-MB-231 and HepG2 cells. The structure activity relationship studies were also investigated. Among them, compound 7e showed better antitumor activity than DCV, and could significantly induce apoptosis in MDA-MB-231 cells. These results represent a step toward the development of novel and improved DCV derivatives.

     

/

返回文章
返回